KPTI, US48576U2050

Karyopharm stock approaches November 2 earnings with USD 33.54 million forecast

Published on 10/17/2026 at 20:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 33.43 million versus USD 37.90 million. Karyopharm stock stood at USD 0.39 on October 16, 2026, up 11.20 percent.

Results and financial scale

MarketBeat estimates third-quarter results for November 2, 2026.
Second-quarter revenue was USD 33.43 million versus USD 37.90 million in the prior-year quarter.
Karyopharm stock was last at USD 0.39 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, up 11.20 percent versus the prior close.
Karyopharm's market capitalization was USD 8.8 million as of October 17, 2026.

KPTI, US48576U2050, Illustration mit AI erstellt.

Karyopharm Therapeutics stock is headed toward the estimated November 2, 2026 release of third-quarter results, with expected revenue of USD 33.54 million, according to MarketBeat. The latest Nasdaq quote was USD 0.39 on October 16, 2026 at 4:00 p.m. ET, up 11.20 percent versus the prior close of USD 0.35.

Revenue reached USD 33.43 million

Karyopharm reported second-quarter revenue of USD 33.43 million, down from USD 37.90 million in the prior-year quarter. The quarter also produced a basic loss of USD 2.32 per share, while total assets stood at USD 111.3 million on June 30, 2026. Those figures place the November report date against a business that is still loss-making and operating with a smaller revenue base than a year earlier.

Stock remains near its yearly low

At USD 0.39 on October 16, 2026, the stock stood USD 0.08 above its 52-week low of USD 0.31 and USD 10.60 below its 52-week high of USD 10.99. That puts the last price 25.81 percent above the low and 96.45 percent below the high. The move from USD 0.35 to USD 0.39 was the main market statistic for the completed Nasdaq session.

Market value and reporting date

Karyopharm's market capitalization was USD 8.8 million as of October 17, 2026. The company is a commercial-stage biotechnology business focused on oncology medicines, including XPOVIO, its oral exportin 1 inhibitor, as described on Karyopharm's investor page. The next reported event is the estimated third-quarter release on November 2, 2026, according to MarketBeat.

The latest Nasdaq quote

Karyopharm was last at USD 0.39 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, up 11.20 percent versus the prior close of USD 0.35. The price remains inside the documented 52-week range, with the low only USD 0.08 away.